# US 2009/0221676 A1 · Glucose-transport related genes, polypeptides, and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0221676 A1
- Document ID: US20090221676A1
- Status: Published application
- Kind: A1
- Application number: 12/393,212
- Filed: 2009-02-26
- Published: 2009-09-03
- Earliest claimed: 2004-12-02
- Assignees: University of Massachusettes
- Inventors: Michael P. Czech; Aimee Powelka; Adilson L. Guilherme; Xiaoqing Tang
- Web page: https://patentgrep.com/patent/US20090221676A1

## CPC

- G01N 33/5023: {on expression patterns}
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C07K 14/62: Insulins
- G01N 33/5008: {for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics}
- G01N 33/5038: {involving detection of metabolites per se}
- G01N 33/5041: {involving analysis of members of signalling pathways}
- G01N 33/5044: {involving specific cell types}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 2333/62: Insulins
- G01N 2800/042: Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
- G01N 2800/044: Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Methods and compositions for modulating glucose transport are provided herein.

## Claims

### Claim 1

A method for identifying a candidate agent that modulates expression or activity of a glucose transport-related polypeptide, the method comprising
(a) providing a sample comprising a glucose-transport related polypeptide or a nucleic acid encoding the polypeptide, wherein the glucose-transport related polypeptide is a gene product of a gene in Table 1 or Table 2;
(b) contacting the sample with a test compound;
(c) evaluating expression or activity of the glucose transport-related polypeptide in the sample; and
(d) comparing the expression or activity of the glucose transport-related polypeptide of (c) to expression or activity of the glucose transport-related polypeptide in a control sample lacking the test compound, wherein a change in glucose transport-related polypeptide expression or activity indicates that the test compound is a candidate agent that can modulate the expression or activity of the glucose transport-related polypeptide.

### Claim 2 (depends on 1)

The method of claim 1, wherein the glucose transport-related polypeptide is a gene product of a gene in Table 1.

### Claim 3 (depends on 1)

The method of claim 1, wherein the glucose transport-related polypeptide is a gene product of a gene in Table 2.

### Claim at position 4

4-17. (canceled)

### Claim 18

A method for modulating glucose transport in a cell, the method comprising:
providing a cell;
contacting the cell with an agent that modulates expression or activity of a glucose transport-related polypeptide, thereby modulating glucose transport in the cell.

### Claim 19 (depends on 1, 18)

The method of claim 18, wherein the agent that modulates expression or activity of a glucose transport-related polypeptide is identified by the method of claim 1.

### Claim 20 (depends on 18)

The method of claim 18, wherein the agent modulates the expression or activity of a gene product of a gene in Table 1 or Table 2.

### Claim 21 (depends on 20)

The method of claim 20, wherein the agent decreases expression or activity of a gene product of a gene in Table 1.

### Claim 22 (depends on 20)

The method of claim 20, wherein the agent increases expression or activity of a gene product of a gene in Table 2.

### Claim 23 (depends on 18)

The method of claim 18, wherein the agent is selected from the group consisting of a polynucleotide, a polypeptide, a small non-nucleic acid organic molecule, a small inorganic molecule, and an antibody.

### Claim 24

(canceled)

### Claim 25 (depends on 23)

The method of claim 23, wherein the agent is selected from the group consisting of an antisense oligonucleotide, an inhibitory RNA, and a ribozyme.

### Claim 26 (depends on 18)

The method of claim 18, further comprising contacting the cell with a second agent that modulates expression or activity of a glucose transport-related polypeptide.

### Claim 27 (depends on 18)

The method of claim 18, wherein the cell is contacted in vitro.

### Claim 28 (depends on 18)

The method of claim 18, wherein the cell is contacted in vivo.

### Claim 29

A method for increasing insulin-stimulated glucose uptake in a subject, the method comprising:
administering to the subject an agent that decreases expression or activity of a gene product of a gene in Table 1 in an amount sufficient to modulate glucose metabolism in a cell of the subject, thereby increasing insulin-stimulated glucose uptake in the subject.

### Claim 30 (depends on 29)

The method of claim 29, wherein the subject is at risk for or suffering from a disorder or condition related to glucose metabolism.

### Claim 31 (depends on 30)

The method of claim 30, wherein the disorder or condition is type I diabetes, type II diabetes, or obesity.

### Claim 32

A method for modulating glucose metabolism in a subject, the method comprising:
administering to the subject an agent that increases expression or activity of a gene product of a gene in Table 2 in an amount sufficient to modulate glucose metabolism in a cell of the subject, thereby modulating glucose metabolism in the subject.

### Claim 33 (depends on 32)

The method of claim 32, wherein the subject is at risk for or suffering from a disorder or condition related to glucose metabolism.

### Claim 34

(canceled)

### Claim 35

A composition comprising a nucleic acid encoding an inhibitory RNA that targets an RNA encoded by a gene of Table 1.

### Claim 36 (depends on 35)

The composition of claim 35, wherein the inhibitory RNA is a small inhibitory RNA.

### Claim 37

(canceled)
